My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 535

Dr Guru Sonpavde - Dana-Farber Cancer Institute, Boston, USA

Dr Sonpavde speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about the STRONG trial, which will look at the use of of fixed-dose durvalumab tremelimumab or durvalumab monotherapy in advanced solid malignancies. 

He outlines that despite initial high response rates to current standard of care first-line chemotherapy, most patients with locally advanced or metastatic urothelial carcinoma eventually experience disease progression.

With no defined standard of care second-line therapies, prognosis remains poor, though immunotherapy offers hope.

When the durvalumab monotherapy cohort is established, the study will look at a fixed dose of durvalumab in combination with tremelimumab, also to be given at a fixed dose every 4 weeks.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence